Biotech Values

[jbog]

10nisman,,,,,


I think it's way to early to even think about a buyout.


When I think about it, because Momenta has such a wide royalty structure with Sandoz, it's that structure that has held the price down for the moment.

Because the FDA did not reject or deny the Amphstar or Teva applications, we'll we'll priced with a large question mark.

In the meantime, I expect Momenta to be able to have the ability to generate very impressive earnings, but once or if the FDA accepts someone else's application we'll sink like a rock.

We'll need to look very carefully at the FDA's 45 page response letter to see if the competition has run into a roadblock. Last night I read in the WSJ that Amphstar group seems to be held up with their Heprin suppliers.


Good Luck